Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. COVID-19 in people with multiple sclerosis: A global data sharing initiative

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Predictors of treatment outcome in patients with paediatric onset multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Reproductive history of the Danish multiple sclerosis population: A register-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Aggressive multiple sclerosis (1): Towards a definition of the phenotype

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Aggressive multiple sclerosis (2): Treatment

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-beta: a GWAS

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Biomarkers of inflammation and epithelial barrier function in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Serum neurofilament light as a biomarker in progressive multiple sclerosis

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

BACKGROUND: Dimethyl fumarate (DMF) is a disease-modifying therapy used for patients with relapsing-remitting multiple sclerosis (RRMS). B cells are important contributors to the pathogenesis of RRMS, where they regulate the inflammatory immune responses and participate in development of lesions in the central nervous system (CNS). The impact of DMF on B cell subpopulations remains incompletely understood.

OBJECTIVES: In this study, we evaluated the effects of DMF on B cell subpopulations and their effector functions.

METHODS: Blood from 21 DMF-treated and 18 untreated patients with RRMS was analyzed by flow cytometry.

RESULTS: We found that DMF reduces the frequency of circulating antigen-experienced B cells, a reduction likely related to a reduced frequency of follicular helper T (TFH) cells and an increased frequency of follicular regulatory T (TFR) cells. Studying the impact of monomethyl fumarate (MMF), the primary metabolite of DMF, on B cell effector function in vitro showed that MMF increased the frequency of transforming growth factor (TGF)-β-producing B cells and decreased the frequency of B cells secreting lymphotoxin (LT)-α, tumor necrosis factor (TNF)-α, interleukin (IL)-6, and to a lesser extent IL-10.

CONCLUSION: In summary, these data suggest an anti-inflammatory role of DMF and its metabolite MMF on the B cell compartment.

Original languageEnglish
JournalMultiple sclerosis
Volume25
Issue number9
Pages (from-to)1289-1297
Number of pages9
ISSN1352-4585
DOIs
Publication statusPublished - Aug 2019

ID: 58577613